Ionis Faces Legal Scrutiny Amid Slashed Sales Forecast
Ionis Pharmaceuticals Takes a Hit: What's Happening? November 9, 2026, wasn't just another dreary market day—especially if you've got a stake in Ionis Pharmaceuticals. Today, they whittled down their full-year sales forecast for TRYNGOLZA from a cozy $100 million to $110 million range to a startling $50 million. NASDAQ: IONS shares naturally took a nosedive, and as...
Continue Reading